| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $100.0M | — |
| R&D Expense | $3.9M | -19.8% |
| SG&A Expense | $7.9M | +57.1% |
| Operating Income | -$11.9M | -19.3% |
| Net Income | -$14.6M | -6.3% |
| EPS (Basic) | -$2.02 | +47.4% |
| EPS (Diluted) | -$2.02 | +47.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $48.5M | +3357.3% |
| Inventory | $615K | — |
| Current Assets | $50.3M | +2519.4% |
| Total Assets | $50.7M | +1969.1% |
| Current Liabilities | $3.4M | +28.1% |
| Total Liabilities | $9.3M | +29.6% |
| Stockholders' Equity | $41.5M | +981.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.8M | +11.9% |
| Capital Expenditures | $27K | — |
| Investing Cash Flow | -$27K | — |
| Financing Cash Flow | $54.9M | +566.5% |
| Free Cash Flow | -$7.8M | — |